Global Antibody Drug Conjugates Contract Manufacturing Market – Industry Trends and Forecast to 2029

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Global Antibody Drug Conjugates Contract Manufacturing Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Páginas
  • Número de tablas: 220
  • Número de figuras: 60

Global Antibody Drug Conjugates Contract Manufacturing Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2022 –2029
Diagram Tamaño del mercado (año base)
USD 8.20 Billion
Diagram Tamaño del mercado (año de pronóstico)
USD 12.35 Billion
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Antibody Drug Conjugates Contract Manufacturing Market, By Condition (Myeloma, Lymphoma, Breast Cancer, Others (Urothelial Cancer), Linker (Cleavable Linker, Non-cleavable) – Industry Trends and Forecast to 2029

Antibody Drug Conjugates Contract Manufacturing Market

Antibody Drug Conjugates Contract Manufacturing Market Analysis and Size

Drug and antibody conjugate. ADCs, also known as antibody-drug conjugates, are a family of biopharmaceutical medications created as a targeted therapy for cancer treatment. ADCs are designed to target and destroy tumour cells while protecting healthy cells, in contrast to chemotherapy.

Data Bridge Market Research analyses that the antibody drug conjugates contract manufacturing market which was USD 8.2 billion in 2021, would rocket up to USD 12.35 billion by 2029, and is expected to undergo a CAGR of 5.25% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Antibody Drug Conjugates Contract Manufacturing Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Condition (Myeloma, Lymphoma, Breast Cancer, Others (Urothelial Cancer), Linker (Cleavable Linker, Non-cleavable)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Samsung Biologics (South Korea), Lonza (Switzerland), Catalent Inc. (U.S.), Siegfried Holding AG (Switzerland), Piramal Pharma Solutions (India), Boehringer Ingelheim International GmbH (Germany)

Market Opportunities

  • Rising need for biologic therapy
  • Rising cancer prevalence

Market Definition

One of the anticancer medications with the quickest growth is antibody-drug conjugates (ADC). This method uses a mAb attached to a lethal payload via a chemical linker that is directed at a target antigen expressed on the surface of the cancer cell, limiting systemic exposure and toxicity. ADCs are intricate molecules that need special consideration for a number of factors.

Antibody Drug Conjugates Contract Manufacturing Market Dynamics

Drivers

  • Increase in demand of medicines

The market's growth is primarily driven by two factors: the increase in the need for medicines on a global scale and the advantage of lower total development costs with contract manufacturing.

  • Rise in the geriatric population

The rising prevalence rates of lifestyle disorders like rising health-care spending, and the fast-growing diagnostic industry are driving the antibody drug conjugates contract manufacturing market expansion.

Opportunities

  • Rise in cancer cases

The market is predicted to have considerable expansion over the course of the forecast period due to factors including rising need for biologic therapy, rising cancer prevalence, and outsourcing of operations and services to contract manufacturing companies.

Restraints/Challenges

The high cost of medicine development and distribution, on the other hand, will impede the market's rate of expansion. The market will be challenged by the shortage of trained personnel and inadequate healthcare infrastructure in developing nations.

This antibody drug conjugates contract manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antibody drug conjugates contract manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Antibody Drug Conjugates Contract Manufacturing Market

The COVID-19 pandemic prompted the creation of COVID-19 vaccinations, antibody treatments, antiviral medications, and numerous other associated pharmaceutical items. Brazil, India, the United States, and several important European nations were severely affected by the epidemic, which increased demand for biopharmaceutical goods and, as a result, medicine production. To assure the quality and safety of their products, vaccines and biologics require specialised production and fill-finish techniques. This calls for highly developed analytical skills and flexible aseptic fill-finish technology. As a result, covid-19 had a favourable effect on the market.

Global Antibody Drug Conjugates Contract Manufacturing Market Scope

The antibody drug conjugates contract manufacturing market is segmented on the basis of condition, linker. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Condition

  • Myeloma
  • Lymphoma
  • Breast Cancer
  • Others (Urothelial Cancer)

Linker

  • Cleavable Linker
  • Non-cleavable Linker

Antibody Drug Conjugates Contract Manufacturing Market Regional Analysis/Insights

The antibody drug conjugates contract manufacturing market is analysed and market size insights and trends are provided by country, condition, linker as referenced above.

The countries covered in the antibody drug conjugates contract manufacturing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the antibody drug conjugates contract manufacturing market due to the growing number of geriatric population along with adoption of innovative medical technology.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the increase in the outsourcing operations to contract manufacturing organizations.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Antibody Drug Conjugates Contract Manufacturing Market Share Analysis

The antibody drug conjugates contract manufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antibody drug conjugates contract manufacturing market.

Some of the major players operating in the antibody drug conjugates contract manufacturing market are:

  • Samsung Biologics (South Korea)
  • Lonza (Switzerland)
  • Catalent Inc. (U.S.)
  • Siegfried Holding AG (Switzerland)
  • Piramal Pharma Solutions (India)
  • Boehringer Ingelheim International GmbH (Germany)


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Antibody Drug Conjugates Contract Manufacturing Market size will be worth USD 12.35 billion By 2029.
The Antibody Drug Conjugates Contract Manufacturing Market growth rate will be 5.25% by 2029.
Increase in demand of medicines and Rise in the geriatric population are the growth drivers of the Antibody Drug Conjugates Contract Manufacturing Market.
The condition and linker are the factors on which the Antibody Drug Conjugates Contract Manufacturing Market research is based.
The major companies in the Antibody Drug Conjugates Contract Manufacturing Market are Samsung Biologics (South Korea), Lonza (Switzerland), Catalent Inc. (U.S.), Siegfried Holding AG (Switzerland), Piramal Pharma Solutions (India), Boehringer Ingelheim International GmbH (Germany).